Cost-effectiveness journal article published

Study shows the cost-effectiveness of SurroSense Rx® as an adjunct to standard diabetic foot care

Calgary, AB, Canada, February 22, 2018  – Orpyx Medical Technologies Inc. announced today the publication of “Cost effectiveness of smart insoles in preventing ulcer recurrence for people in diabetic foot remission” in Wound Care Management. The analysis shows the cost-effectiveness of smart insoles as an adjunct to standard diabetic foot care. A pilot study completed at the University of Arizona’s Southern Arizona Limb Salvage Alliance (SALSA) provided clinical inputs for two decision tree models-one at three-months and one at eighteen-months post diabetic foot ulcer (DFU) closure, comparing current standard of care to use of the SurroSense Rx system as an adjunct to standard of care (SOC).

Results from the cost-effectiveness analysis indicate that short-term (three-month) adjunctive use of the SurroSense Rx brings costs per event avoided to approximately US$463 (from US$1,376 for SOC alone), while long-term (eighteen-month) adjunctive use brings costs per event avoided to approximately US$6,700 (from US$53,135 for SOC alone). The results also suggest that adjunctive use of the SurroSense Rx reduces event occurrence rates, with both long- and short-term use.

“We are very excited to see strong positive results from this study.” said Dr. Breanne Everett, co-founder and CEO of Orpyx Medical Technologies Inc. “It helps to confirm what we’ve long believed at Orpyx – that the SurroSense Rx system is a more cost-effective means of preventing DFUs and offers the opportunity for substantial savings for healthcare systems and insurance providers around the world.”

According to the analysis, the SurroSense Rx device, when used as an adjunct to the current standard of care, is a cost-effective means of preventing DFU recurrence, resulting in an overall cost of care that is over 70% lower than current expected cost of care with standard of care alone. Further, the adoption of the device remains cost-neutral or better when the cost of the device is less than US$14,275.

It concludes that, with foot ulcer care comprising a large portion of the direct cost of diabetic care, the SurroSense Rx system shows promise in cost-effectively managing patients at a high risk of diabetic foot complications.

About Orpyx Medical Technologies Inc.
Orpyx Medical Technologies Inc. (“Orpyx”) is a wearable pressure sensor technology company focused on medical applications. Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, peripheral neuropathy, which leads to lack of circulation, numbness, or loss of protective sensation, in the feet. This problem leads to the development of foot ulcers which can ultimately lead to amputation and death infection and ulcers in the feet, also known as peripheral neuropathy. Additionally, this problem affects upwards of 60% of diabetics over the course of their disease and costs the North American health care system over $16.4 billion annually.

For more information, please contact:
Chan Mean
Marketing Manager, Orpyx Medical Technologies Inc.
chan.mean@orpyx.com
+1 403 460 0216 ext. 501